ライフサイエンスコーパス: multinational

1 bservational Program (TOP) is an open-label, multinational, 10-year prospective study in clinical pra

2 31) in a 26-week open-label, parallel-group, multinational (15 countries) study.

3 The study was a 6-month randomized multinational (17 countries) and multicenter (102 invest

4 att hours/square meters/day) on the basis of multinational and cross-state studies.

5 Herein, a multinational and multidisciplinary panel of neuro-oncol

6 al Arabidopsis community, represented by the Multinational Arabidopsis Steering Committee (MASC), has

7 low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer

8 t beginning with a validated risk index (eg, Multinational Association for Supportive Care in Cancer

9 ary, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer

10 Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer

11 ients) and online anonymized surveys of 1225 multinational BC patients and survivors were also conduc

12 on outcomes were compared in the prospective multinational Berlin-Frankfurt-Muenster (BFM) study grou

13 The RESTORE trial was a multinational, blinded placebo-controlled study of 2,197

14 We identify critical habitats across multinational boundaries and show that top predators exp

15 ion of patient-reported outcomes (PROs) into multinational cancer clinical trials in the cancer coope

16 ence is to develop prospective, national and multinational case registries to determine the range of

17 We performed a multinational case-control study that included 51 kidney

18 emergence of Asian retail developing-country multinational chains.

19 hepatitis C are enrolled in multicenter and multinational clinical protocols and therapeutic trials.

20 andomized, double-blind, placebo-controlled, multinational clinical trial of 6560 patients within 48

21 andomized, double-blind, placebo-controlled, multinational clinical trial with a 24-week treatment pe

22 In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (

23 ed and validated in rigorous multicenter and multinational clinical trials aimed at gaining regulator

24 eumonia (HAP) enrolled in two registrational multinational clinical trials for the genetic elements c

25 clerosis (SSc)-related digital ulcers in two multinational clinical trials; and although statin thera

26 We analysed an independent multinational cohort comprising 3100 patients with neuro

27 rithm were assessed by blinded analysis of a multinational cohort of 834 patients with molecularly co

28 In a multinational cohort of AHF, we examined the ability of

29 In a multinational cohort of critically ill children with sev

30 incident HPV infections to GW detection in a multinational cohort of men aged 18-70 years.

31 Using a prospective, multinational cohort of patients with definite NVE, the

32 characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB a

33 In this prospective, multinational cohort of patients with S. aureus PVIE, EV

34 In a multinational cohort of patients with stable angina, the

35 thogenesis of food allergies and multicenter-multinational cohort studies will elucidate interactions

36 This retrospective multinational cohort study included patients from 25 oph

37 Registry of Acute Coronary Events (GRACE), a multinational cohort study, 44 372 patients with an ACS

38 In this large, prospective, multinational cohort, more than one half of all cases of

39 e, and loss to follow-up were from published multinational cohorts in low-income and middle-income co

40 implemented in 2002 after its validation in multinational cohorts including patients from cancer cen

41 lity following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts

42 e diagnostic criteria, there is a need for a multinational collaboration to produce a prospective dat

43 We performed a multinational collaborative study, which included assess

44 Using a multinational collection of isolates from methicillin-re

45 Using multinational collections of methicillin-susceptible Sta

46 We randomly assigned 878 employees of a multinational company based in the United States to rece

47 Multinational comparisons demonstrate marked ethnic and

48 A multinational consensus meeting of multidisciplinary exp

49 Multinational conservation initiatives that prioritize i

50 brain and intracranial volumes from a large multinational consortium.

51 carditis-Microbiology, a large, multicenter, multinational consortium.

52 In this review, we summarize the progress of multinational control initiatives against Chagas disease

53 ugh a variety of business relationships with multinational corporations as a means of underwriting th

54 Multinational corporations play a prominent role in shap

55 uropean Union, with the backing of their own multinational corporations, believe that these new power

56 o objectively track sleep-wake dynamics in a multinational crew of six during 520 d of confined isola

57 A multinational cross-sectional study of children with ARP

58 In this multinational cross-sectional study, 322 physicians from

59 the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess

60 e first prospectively declared collaborative multinational database, including individual data of pat

61 Between July, 2008, and June, 2010, we did a multinational double-blind, randomised, phase 2 study co

62 In this multinational, double-blind, 24 week study, we enrolled

63 SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial th

64 sistant prostate cancer were enrolled into a multinational, double-blind, placebo-controlled trial.

65 We did this randomised, multinational, double-blind, placebo-controlled, phase 2

66 In this phase 3, multinational, double-blind, randomised controlled trial

67 In this phase 3, multinational, double-blind, randomised, controlled tria

68 EORTC 18071 was a multinational, double-blind, randomised, phase 3 trial i

69 DESIGN, SETTING, AND PARTICIPANTS: Multinational, double-blind, randomized placebo-controll

70 In this multinational, double-blind, randomized trial, we compar

71 Here we describe a multinational drug discovery programme that has delivere

72 Aggregate data from a multinational effort show that in mothers at high risk o

73 As part of a multinational effort to introduce C4 traits into rice to

74 The largest multinational European birth cohort study on food allerg

75 The multinational European study recruited 999 patients with

76 ically considered the available evidence and multinational expert criticism, revised the Rome II diag

77 a Guideline Panel is a multidisciplinary and multinational group composed of experts in pediatric onc

78 a Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and

79 risk anal human papillomavirus (HPV) among a multinational group of men who have sex with men (MSM) a

80 five years of implementation (2008-2013) of multinational health adaptation projects in Albania, Bar

81 lidity and improve instrument reliability in multinational health services research studies involving

82 ted within the HPV Infection in Men Study, a multinational HPV cohort study.

83 is research included building linkages among multinational, interdisciplinary team members, generatin

84 In the main publication of the multinational Interphone Study, investigators concluded

85 The ongoing multinational Justification for the Use of statins in Pr

86 We conducted six parallel, multinational lipid-lowering trials enrolling 4300 patie

87 T1-genotyped subjects with 34 mutations from multinational long QT syndrome registries were studied.

88 examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with

89 We also surveyed three multinational manufacturers who supply influenza vaccine

90 ], Gutenberg Health Study [GHS; n=4354], and Multinational Monitoring of Trends and Determinants in C

91 al study of cardiovascular risk factors (the Multinational mONItoring of trends and determinants in C

92 centers, that had participated in a 6-month multinational multicenter randomized clinical trial (RCT

93 national Forum of Ophthalmic Simulation is a multinational, multicenter collaborative established to

94 Phase 3, multinational, multicenter, 26-week, randomized, open-la

95 FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study.

96 urvival as part of the Global Fluid Study, a multinational, multicenter, prospective, combined incide

97 -paroxysmal atrial fibrillation is the first multinational, multicenter, prospective, noninferiority

98 This was an 8-week multinational, multicenter, randomized, double-blind, pl

99 E5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, pl

100 We conducted a multinational, multicenter, retrospective cohort study,

101 ond largest kingdom of eukaryotic life, by a multinational, multilaboratory consortium.

102 In spite of the multinational nature of the study, sample size is a limi

103 We conducted a large, randomized, multinational, noninferiority trial to determine whether

104 This multinational observational retrospective population-bas

105 In this multinational observational study, improvements in the m

106 s and their clinical isolates collected in a multinational, observational cohort study to determine i

107 This multinational, open-label study included 10 adults with

108 perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-00

109 In this phase 3, randomised, multinational, open-label, non-inferiority trial, we enr

110 The present study was a multinational, open-label, single-arm, phase 3 prophylax

111 Of the 53 experts invited to participate, a multinational panel of 35 (66%) individuals with a mean

112 ve, observational, Internet-based study with multinational participation included 197 ophthalmic clin

113 This was a prospective, multinational pharmacokinetic point-prevalence study inc

114 is randomised, double-blind, parallel-group, multinational phase 3 study, patients aged 70 years or o

115 This multinational phase 3 trial involved adults who had acti

116 We conducted a double-blind, multinational phase IIb trial of 556 men and women with

117 ective in this population than is implied by multinational phase III controlled trials.

118 Data were analyzed from a large, randomized, multinational phase III registration trial involving 271

119 distribution of genotypes in patients from 2 multinational phase III studies of adefovir dipivoxil.

120 A pivotal multinational phase III trial of the Biopure product HBO

121 ouble-blind, placebo-controlled, randomized, multinational phase III trial, 1,144 patients with human

122 solates from patients enrolled in two large, multinational phase three clinical trials assessing tela

123 ated pneumonia, compared with meropenem in a multinational, phase 3, double-blind, non-inferiority tr

124 A multinational, phase 3, double-blind, placebo-controlled

125 In this multinational, phase 3, observer-blinded study, we rando

126 on-inferiority, parallel-group, multicentre, multinational, phase 3a trial (SUSTAIN 4) at 196 sites i

127 A multinational, phase III trial (SYMMETRY) of E + P compa

128 andomized, double-blind, placebo-controlled, multinational, phase III trial included adults with a hi

129 ta from two ongoing, randomised, open-label, multinational, phase III, RESIST studies.

130 We conducted a multinational placebo-controlled trial, in which 1195 pa

131 and funding, not least because of ambitious multinational projects that aim to increase crop yields

132 ly be achieved in the context of national or multinational prospective clinical trials incorporating

133 This was a multinational prospective multicenter observational stud

134 METHODS AND We conducted a multinational prospective observational longitudinal stu

135 TRACK-HD is a multinational prospective observational study of Hunting

136 ardial infarction from data collected in the multinational, prospective Global Registry of Acute Coro

137 SIGN, SETTINGS, AND PATIENTS: A multicenter, multinational, prospective management outcome study in 1

138 In two multicenter, multinational, prospective observational studies, a cent

139 We conducted a multinational, prospective study involving patients admi

140 in Chronic Heart Failure) is a multicenter, multinational, prospective, observational study that inc

141 d subsequent overall survival (OS) in large, multinational PTCL cohorts.

142 In this phase 3, multicenter, multinational, randomised controlled trial, we included

143 These data support the initiation of a multinational, randomised, controlled trial of intrathec

144 SPORT) included in this pooled analysis were multinational, randomised, double-blind, placebo-control

145 We did this multinational, randomised, double-blind, placebo-control

146 cal data collected in the ARISTOTLE trial, a multinational randomized clinical trial that observed 18

147 bloodstream isolates collected as part of a multinational randomized clinical trial, USA 300 and pvl

148 A prospective, multinational randomized controlled trial (RCT) and a co

149 gies through large well designed multicentre-multinational randomized controlled trials incorporating

150 The Mainsail trial was a multinational randomized phase 3 study of 1059 patients

151 on of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomatic patients w

152 36 cases, 234 controls]) was nested within a multinational randomized trial of ART efficacy (Prospect

153 We report the results of a multinational randomized, double-blind study, in which p

154 d in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial between January

155 Multinational, randomized clinical trial conducted at 20

156 ance and subtype with virologic failure in a multinational, randomized clinical trial that evaluated

157 Cancer of the Endometrium (LACE) trial was a multinational, randomized equivalence trial conducted be

158 This double-blind, placebo-controlled, multinational, randomized study included 116 subjects di

159 We conducted a multinational, randomized study to compare radiotherapy

160 INOVATE-HF was a multinational, randomized trial involving 85 centers inc

161 In this multicenter, multinational, randomized, crossover trial, we assessed

162 l was a secondary objective of COU-AA-301, a multinational, randomized, double-blind phase III trial

163 ombolysis In Myocardial Infarction 50) was a multinational, randomized, double-blind, placebo-control

164 A multinational, randomized, placebo-controlled trial (Pla

165 e Questionnaire (MLHFQ) was used in a large, multinational, randomized, placebo-controlled trial to m

166 The aim of this multinational registry is to present a real-world overvi

167 The largest multinational registry of patients in whom acute pulmona

168 ltidisciplinary and increasingly cooperative multinational research effort.

169 controversy surrounding clinical (especially multinational) research, the 52nd general assembly of th

170 A multinational retrospective cohort study of patients wit

171 We included in this multinational retrospective study 112 recipients diagnos

172 eristics of PCSK9 GOF mutation carriers in a multinational retrospective, cross-sectional, observatio

173 We did a multicentre, multinational, retrospective cohort study using individu

174 This study is a multinational, retrospective review of patients treated

175 This multinational, retrospective study of 4301 pancreatoduod

176 6 weeks, and placebo-treated patients from a multinational sample who subsequently received etanercep

177 aseline, patients with AS in both the US and multinational samples had significantly lower scores tha

178 this trial population, recruited in diverse multinational settings.

179 417 Mycobacterium tuberculosis isolates from multinational sites with a high prevalence of drug resis

180 At 302 multinational sites, 5,010 patients in New York Heart As

181 The prospective multinational SMS (Substrate Modification Study) was des

182 t of the full AIDS Clinical Trials Group 204 multinational study (1227 patients), a randomized, contr

183 n children 6 months to <10 years of age in a multinational study conducted during 2010-2011.

184 This double-blind, randomized, multicenter, multinational study enrolled 602 patients, all of whom w

185 This multinational study from 5 centers demonstrates that LRR

186 enrolled in CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) and related this t

187 CardShock is a prospective European multinational study of cardiogenic shock.

188 We performed a prospective, multinational study of Klebsiella pneumoniae bacteremia

189 Prospective, cross-sectional, multicenter, multinational study of pain intensity associated with 12

190 In this multinational study of patients referred for coronary co

191 on of therapeutic strategies, we conducted a multinational study of the natural history and imaging f

192 andomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreot

193 ajority receiving folic acid) and 62% of the multinational study patients (majority not receiving fol

194 d in 93% of US study patients and 94% of the multinational study patients.

195 Among a multinational study population, 46.5% of participants wi

196 This multicenter multinational study shows lack of phenotypic differences

197 This multinational study shows major concerns in the delivery

198 No multinational study to compare the perceptions of medica

199 We performed a large prospective multinational study to study the ability to remove these

200 The Breathing Not Properly Multinational Study was a prospective diagnostic test ev

201 The Breathing Not Properly Multinational Study was a seven-center, prospective stud

202 omized, placebo-controlled, parallel-design, multinational study was conducted.

203 The goal of this multicenter, multinational study was to determine the safety and prel

204 The aim of this multinational study was to measure and describe the perc

205 In a multinational study, 519 patients with newly diagnosed c

206 In a cross-sectional, multinational study, all-cause and ASCVD mortality rates

207 In a double-blind phase 2 multinational study, conducted from April 2005 to Octobe

208 In a large prospective multinational study, removal success of FCSEMS after ext

209 In this multinational study, there was variation across countrie

210 In this large multinational study, treatment with SGLT-2i versus other

211 was a phase II, observer-blind, randomized, multinational study.

212 The use of multinational surveillance systems to guide the manageme

213 The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively plan

214 follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in dis

215 international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

216 omised, open-label, two-arm, parallel-group, multinational, treat-to-target, non-inferiority trial do

217 In a multinational trial (V325), 445 patients were randomly a

218 In this large multinational trial among patients undergoing cardiac su

219 ilure trials, the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Grupp

220 ents enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial (n=1

221 ion with HF from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

222 measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), could be used to

223 Morbidity], CORONA [Controlled Rosuvastatin Multinational Trial in Heart Failure], and MAGGIC [Meta-

224 of patients from the Controlled Rosuvastatin Multinational Trial in HF (CORONA) study.

225 -REF trials, and the Controlled Rosuvastatin Multinational Trial in HF-REF (CORONA).

226 al report the results of LYM-2034, a phase 2 multinational trial in which 164 patients with nongermin

227 In this multinational trial involving patients with a PFO who ha

228 in the first large randomized, double-blind multinational trial of this therapeutic modality for rag

229 l Infarction 25) study, a large, randomized, multinational trial, demonstrated a reduction in death o

230 In this randomized, double-blind, multinational trial, we assessed the efficacy and safety

231 In a double-blind, multinational trial, we randomly assigned 330 patients w

232 apies were treated in this pivotal phase II, multinational trial.

233 a-2a (40 kd) plus ribavirin in a randomized, multinational trial.

234 Ongoing multinational trials are pursuing whether reducing infla

235 In six multinational trials evaluating bococizumab, antidrug an

236 Two multinational trials were conducted to compare the effic

237 In two parallel, multinational trials with different entry criteria for L

238 on treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) stu

239 y artery disease, and stable angina from the multinational Type 2 Diabetes Evaluation of Ranolazine i

240 Initially, MVP envisioned partnering with a multinational vaccine manufacturer, but the target price

241 rrelates for survival were evaluated using a multinational valve-in-valve registry that included 459

242 es a range of successful strategies from the multinational Vision 2020 Initiative to disease-specific